Skip to main
NBTX

Nanobiotix SA (NBTX) Stock Forecast & Price Target

Nanobiotix SA (NBTX) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 33%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Nanobiotix is a promising biotechnology company with a unique and innovative approach to developing nanotherapeutics for a wide range of diseases. The company's strong financial position, including a significant cash runway and a recent follow-on offering, provides confidence in its ability to continue its research and development efforts. While facing some risks, including logistical challenges and potential clinical trial setbacks, Nanobiotix's collaboration with JNJ and promising data for its lead program, NBTXR3, position it well for potential commercial success in multiple indications with a significant potential total addressable market size. The recently updated price target of $36, reflecting increased confidence in the company's potential, suggests a positive future outlook for Nanobiotix's stock.

Bears say

Nanobiotix is facing potential challenges with their novel radioenhancer NBTXR3, despite recent positive data updates in stage III unresectable non-small cell lung cancer and locally advanced squamous-cell carcinoma of the head and neck. There are also risks associated with potential product failures, legal issues, and competition. The recent patent applications for the Curadigm platform provide some potential for future growth, but the company still faces overall risks in their research, development, and regulatory processes. Financially, the company relies on funding from partnerships and dilutive financing, which could lead to lower-than-expected sales and financial results.

Nanobiotix SA (NBTX) has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 33% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Nanobiotix SA and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Nanobiotix SA (NBTX) Forecast

Analysts have given Nanobiotix SA (NBTX) a Buy based on their latest research and market trends.

According to 3 analysts, Nanobiotix SA (NBTX) has a Buy consensus rating as of Aug 24, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $37.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $37.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Nanobiotix SA (NBTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.